Thiazolidinediones alter growth and epithelial cell integrity, independent of PPAR-γ and MAPK activation, in mouse M1 cortical collecting duct cells

被引:3
作者
Nasrallah, Rania [1 ]
Clark, Jordan [1 ]
Corinaldi, Jaime [1 ]
Paris, Genevieve [1 ]
Miura, Pedro [1 ]
Jasmin, Bernard J. [1 ]
Hebert, Richard L. [1 ]
机构
[1] Univ Ottawa, Fac Med, Kidney Res Ctr, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada
关键词
M1 collecting duct cells; troglitazone; rosiglitazone; PEROXISOME-PROLIFERATOR; RECEPTOR-GAMMA; BETA-CATENIN; EXPRESSION; MECHANISMS; SUPERFAMILY; ALPHA;
D O I
10.1152/ajprenal.00735.2009
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Nasrallah R, Clark J, Corinaldi J, Paris G, Miura P, Jasmin BJ, Hebert RL. Thiazolidinediones alter growth and epithelial cell integrity, independent of PPAR-gamma and MAPK activation, in mouse M1 cortical collecting duct cells. Am J Physiol Renal Physiol 298: F1105-F1112, 2010. First published February 17, 2010; doi:10.1152/ajprenal.00735.2009.-Peroxisome proliferator-activated receptor (PPAR)-gamma is highly expressed in the collecting duct (CD), yet little is known about the effects of PPAR-gamma ligands, thiazolidinediones (TZDs), on CD cell structure and function. M1 mouse cortical CD cells were treated with 5 mu M troglitazone (TRO) and rosiglitazone (ROSI). First, growth was measured by [H-3] thymidine and [H-3] leucine incorporation, as well as analysis of cyclin D1 and the CDK inhibitor p27 by Western blot. [H-3] thymidine incorporation was reduced by 56 and 24% by TRO and ROSI at 6 h, and [H-3] leucine by 21 and 10%. A similar growth inhibition was also observed after 24 h for thymidine, but leucine was reduced by 48 and 24%, respectively. Likewise, cyclin D1 was diminished 60% by TRO, and p27 was elevated 1.6- and 1.7-fold in response to TRO and ROSI. Next, epithelial cell integrity was assessed by measuring different markers by Western blot analysis. While fibronectin and alpha-smooth muscle actin levels were unchanged, by 24 h E-cadherin was decreased by 50%, and beta-catenin levels were reduced 2- and 1.5-fold in response to TRO and ROSI, respectively. GW9662, a PPAR-gamma antagonist, did not reverse any of the TZD responses in M1 cells. Of interest, phosho-p38 levels were also elevated 2- fold in response to TRO and 2.3-fold to ROSI, but MAPK inhibition by PD98059 or SB203580 caused an additive inhibition of cell growth and did not alter E-cadherin or beta-catenin in response to TZDs. Finally, apoptotic death was assessed by Western blot, but cleaved caspase-3 levels were unchanged from 15 min to 24 h in response to TZDs, and TRO did not affect cell viability or reactive oxygen species generation. Our data suggest that TZDs cause a disruption of M1 cell integrity that is preceded by an inhibition of cell growth. This response is independent of p38 or PPAR-gamma activation.
引用
收藏
页码:F1105 / F1112
页数:8
相关论文
共 40 条
  • [1] PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?
    Ahmed, W.
    Ziouzenkova, O.
    Brown, J.
    Devchand, P.
    Francis, S.
    Kadakia, M.
    Kanda, T.
    Orasanu, G.
    Sharlach, M.
    Zandbergen, F.
    Plutzky, J.
    [J]. JOURNAL OF INTERNAL MEDICINE, 2007, 262 (02) : 184 - 198
  • [2] Peroxisome proliferator-activated receptor γ regulates E-cadherin expression and inhibits growth and invasion of prostate cancer
    Annicotte, Jean-Sebastien
    Iankova, Irena
    Miard, Stephanie
    Fritz, Vanessa
    Sarruf, David
    Abella, Anna
    Berthe, Marie-Laurence
    Noel, Daniele
    Pillon, Arnaud
    Iborra, Francois
    Dubus, Pierre
    Maudelonde, Thierry
    Culine, Stephane
    Fajas, Lluis
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2006, 26 (20) : 7561 - 7574
  • [3] Thiazolidinediones in dermatology
    Boyd, Alan S.
    [J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 2007, 46 (06) : 557 - 563
  • [4] Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets
    Brown, Jonathan D.
    Plutzky, Jorge
    [J]. CIRCULATION, 2007, 115 (04) : 518 - 533
  • [5] PPAR-α and -γ agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse
    Calkin, Anna C.
    Giunti, Sara
    Jandeleit-Dahm, Karin A.
    Allen, Terri J.
    Cooper, Mark E.
    Thomas, Merlin C.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (09) : 2399 - 2405
  • [6] Cheng HC, 2008, MOL VIS, V14, P95
  • [7] Effects of thiazolidinediones on differentiation, proliferation, and apoptosis
    Chou, Fu-Sheng
    Wang, Pei-Shan
    Kulp, Samuel
    Pinzone, Joseph J.
    [J]. MOLECULAR CANCER RESEARCH, 2007, 5 (06) : 523 - 530
  • [8] CLARK J, 2009, PPAR RES, P1
  • [9] Magnitude of peroxisome proliferator-activated receptor-γ activation is associated with important and seemingly opposite biological responses in breast cancer cells
    Clay, CE
    Namen, AM
    Atsumi, G
    Trimboli, AJ
    Fonteh, AN
    High, KP
    Chilton, FH
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2001, 49 (05) : 413 - 420
  • [10] Cyclin D1 inhibits peroxisome proliferator-activated receptor γ-mediated adipogenesis through histone deacetylase recruitment
    Fu, MF
    Rao, M
    Bouras, T
    Wang, CG
    Wu, KM
    Zhang, XP
    Li, ZP
    Yao, TP
    Pestell, RG
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (17) : 16934 - 16941